Hong Kong · Delayed Price · Currency is HKD Immunotech Biopharm Statistics
Total Valuation
HKG:6978 has a market cap or net worth of HKD 1.60 billion. The enterprise value is 2.04 billion.
| Market Cap | 1.60B |
| Enterprise Value | 2.04B |
Important Dates
The next estimated earnings date is Friday, March 27, 2026.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HKG:6978 has 617.50 million shares outstanding.
| Current Share Class | 617.50M |
| Shares Outstanding | 617.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 34.64% |
| Owned by Institutions (%) | 0.04% |
| Float | 222.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -10.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -8.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -17.29 |
Financial Position
The company has a current ratio of 0.08
| Current Ratio | 0.08 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -3.99 |
| Interest Coverage | -24.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -17.94% |
| Return on Invested Capital (ROIC) | -28.08% |
| Return on Capital Employed (ROCE) | 2,270.98% |
| Weighted Average Cost of Capital (WACC) | 5.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.42M |
| Employee Count | 173 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, HKG:6978 has paid 1.02 million in taxes.
| Income Tax | 1.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.39% in the last 52 weeks. The beta is 0.56, so HKG:6978's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | +0.39% |
| 50-Day Moving Average | 2.75 |
| 200-Day Moving Average | 3.57 |
| Relative Strength Index (RSI) | 46.86 |
| Average Volume (20 Days) | 306,812 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -190.12M |
| Pretax Income | -244.24M |
| Net Income | -244.91M |
| EBITDA | -126.75M |
| EBIT | -190.12M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
The company has 23.07 million in cash and 471.54 million in debt, with a net cash position of -448.47 million or -0.73 per share.
| Cash & Cash Equivalents | 23.07M |
| Total Debt | 471.54M |
| Net Cash | -448.47M |
| Net Cash Per Share | -0.73 |
| Equity (Book Value) | -159.42M |
| Book Value Per Share | -0.30 |
| Working Capital | -499.43M |
Cash Flow
In the last 12 months, operating cash flow was -100.15 million and capital expenditures -18.11 million, giving a free cash flow of -118.26 million.
| Operating Cash Flow | -100.15M |
| Capital Expenditures | -18.11M |
| Free Cash Flow | -118.26M |
| FCF Per Share | -0.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HKG:6978 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -15.31% |
| FCF Yield | -7.39% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |